Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Looks To New CFO Hippe To Help Steel Itself For Restructuring

This article was originally published in The Pink Sheet Daily

Executive Summary

Alan Hippe will replace CFO Erich Hunziker as Roche implements its radical cost-cutting plan.

You may also be interested in...



Implementation of Roche's 'Operational Excellence' Initiative Will Trim Nearly 5,000 Sales, Manufacturing and R&D Jobs

Roche characterized the anticipated restructuring plan as a pre-emptive strike and maintained that the integration of Genentech was successful and continuing apace.

Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty

Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.

Roche Wins Genentech After Months-Long Battle

The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel